Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359412 | 0.96 | DPP4 (0.50) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3359409 | 0.96 | DPP4 (0.50) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL31448430 | 0.94 | DPP4 (0.48) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30552684 | 0.94 | DPP4 (0.48) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29411145 | 0.89 | DPP4 (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL31497255 | 0.89 | DPP4 (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29816377 | 0.89 | DPP4 (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10793052 | 0.84 | PREP (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10793068 | 0.84 | PREP (0.44) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL29728563 | 0.83 | CHRM2 (0.49) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-01 | — | — | US | disclosed |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | OHIO STATE INNOVATION FOUNDATION | 2024-10-31 | — | — | US | disclosed |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-11878046-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-09-29 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11351222-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220160819-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | VIP, LNPEP, IAPP | DPP4 1670/4885DPP8 752/4885DPP9 485/4885 |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | SLC3A2, SPPL2B, SLC7A1 | DPP4 409/4885DPP8 526/4885DPP9 298/4885 |
| US-11878046-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | IKBKE, IKBKB, SHARPIN | DPP4 1665/4885DPP8 1190/4885DPP9 1062/4885 |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | DPP4 968/4885DPP8 446/4885DPP9 335/4885 |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | DPP4 968/4885DPP8 446/4885DPP9 335/4885 |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC38A7, SLC7A1, SLC6A7 | DPP4 689/4885DPP8 266/4885DPP9 512/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | DPP4 523/4885DPP8 952/4885DPP9 450/4885 |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | CHN2, TAP2, VIP | DPP4 1003/4885DPP8 392/4885DPP9 172/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | DPP4 1103/4885DPP8 710/4885DPP9 401/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | DPP4 891/4885DPP8 367/4885DPP9 201/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | DPP4 710/4885DPP8 728/4885DPP9 568/4885 |
| US-20220160819-A1 | DI-SULFIDE CONTAINING CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | IKBKE, IKBKB, SHARPIN | DPP4 1665/4885DPP8 1190/4885DPP9 1062/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | DPP4 994/4885DPP8 882/4885DPP9 978/4885 |
| US-11351222-B2 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof | IKBKE, IKBKB, SHARPIN | DPP4 1665/4885DPP8 1190/4885DPP9 1062/4885 |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | DPP4 329/4885DPP8 548/4885DPP9 246/4885 |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | CHN2, TAP2, VIP | DPP4 1003/4885DPP8 392/4885DPP9 172/4885 |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | DPP4 535/4885DPP8 903/4885DPP9 586/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | DPP4 1954/4885DPP8 1126/4885DPP9 861/4885 |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | VIP, LNPEP, NGLY1 | DPP4 857/4885DPP8 342/4885DPP9 189/4885 |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | VIP, LNPEP, TAP1 | DPP4 836/4885DPP8 576/4885DPP9 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.